Patient and transplant characteristics
| Variable . | From N of 20 . | |
|---|---|---|
| Patients | ||
| Patient age, y, median (range) | 56 | (37-66) |
| Male sex | 12 | (60%) |
| Race | ||
| White | 17 | (85%) |
| Black | 3 | (15%) |
| Reason for unrelated donor | ||
| No suitable adult family donor | 12 | (60%) |
| DSAs not amenable to desensitization | 6 | (30%) |
| Familial cancer susceptibility | 2 | (10%) |
| Diagnosis | ||
| Acute myeloid leukemia | 11 | (55%) |
| MDS or MPN | 4* | (20%) |
| Chronic myeloid leukemia in CP2 | 1 | (5%) |
| Non-Hodgkin lymphoma | 4† | (20%) |
| Refined DRI group | ||
| Low risk | 2 | (10%) |
| Intermediate risk | 14 | (70%) |
| High risk | 4 | (20%) |
| Very high risk | 0 | (0%) |
| CR at transplant | 14 | (70%) |
| Post-BMT maintenance therapy | 3‡ | (15%) |
| Unrelated grafts | ||
| HLA matches§ | ||
| 5/10 (1 locus mismatch at A, B, Cw, DRB1, DQB1) | 1 | (5%) |
| 6/10 (1 A, 1 Cw, both B loci mismatched) | 1 | (5%) |
| 7/10 (1 locus mismatch at class I, DRB1, DQB1) | 3 | (15%) |
| 8/10 | 4‖ | (20%) |
| 9/10 | 11¶ | (55%) |
| Class I + II antigen mismatches# | ||
| 3 | 2 | (10%) |
| 2 | 4 | (20%) |
| 1 | 10 | (50%) |
| 0** | 4 | (20%) |
| HLA-C mismatch | 10 | (50%) |
| Complete HLA-DP mismatch | 9 | (45%) |
| ABO incompatibility | 12 | (60%) |
| Major | 7 | (35%) |
| Minor | 4 | (20%) |
| Both major and minor | 1 | (5%) |
| CMV serostatus | ||
| CMV IgG mismatch | 8 | (40%) |
| Patient CMV seropositive | 14 | (70%) |
| Donor age, y, median (range) | 33 | (20-40) |
| Female donor/male recipient | 6 | (30%) |
| Cell dose infused, median (IQR) | ||
| Total nucleated cells × 108/kg†† | 3.2 | (2.7-4.4) |
| CD34+ cells × 106/kg | 2.8 | (2.0-4.9) |
| CD3+ cells × 107/kg | 3.4 | (2.7-5.0) |
| Variable . | From N of 20 . | |
|---|---|---|
| Patients | ||
| Patient age, y, median (range) | 56 | (37-66) |
| Male sex | 12 | (60%) |
| Race | ||
| White | 17 | (85%) |
| Black | 3 | (15%) |
| Reason for unrelated donor | ||
| No suitable adult family donor | 12 | (60%) |
| DSAs not amenable to desensitization | 6 | (30%) |
| Familial cancer susceptibility | 2 | (10%) |
| Diagnosis | ||
| Acute myeloid leukemia | 11 | (55%) |
| MDS or MPN | 4* | (20%) |
| Chronic myeloid leukemia in CP2 | 1 | (5%) |
| Non-Hodgkin lymphoma | 4† | (20%) |
| Refined DRI group | ||
| Low risk | 2 | (10%) |
| Intermediate risk | 14 | (70%) |
| High risk | 4 | (20%) |
| Very high risk | 0 | (0%) |
| CR at transplant | 14 | (70%) |
| Post-BMT maintenance therapy | 3‡ | (15%) |
| Unrelated grafts | ||
| HLA matches§ | ||
| 5/10 (1 locus mismatch at A, B, Cw, DRB1, DQB1) | 1 | (5%) |
| 6/10 (1 A, 1 Cw, both B loci mismatched) | 1 | (5%) |
| 7/10 (1 locus mismatch at class I, DRB1, DQB1) | 3 | (15%) |
| 8/10 | 4‖ | (20%) |
| 9/10 | 11¶ | (55%) |
| Class I + II antigen mismatches# | ||
| 3 | 2 | (10%) |
| 2 | 4 | (20%) |
| 1 | 10 | (50%) |
| 0** | 4 | (20%) |
| HLA-C mismatch | 10 | (50%) |
| Complete HLA-DP mismatch | 9 | (45%) |
| ABO incompatibility | 12 | (60%) |
| Major | 7 | (35%) |
| Minor | 4 | (20%) |
| Both major and minor | 1 | (5%) |
| CMV serostatus | ||
| CMV IgG mismatch | 8 | (40%) |
| Patient CMV seropositive | 14 | (70%) |
| Donor age, y, median (range) | 33 | (20-40) |
| Female donor/male recipient | 6 | (30%) |
| Cell dose infused, median (IQR) | ||
| Total nucleated cells × 108/kg†† | 3.2 | (2.7-4.4) |
| CD34+ cells × 106/kg | 2.8 | (2.0-4.9) |
| CD3+ cells × 107/kg | 3.4 | (2.7-5.0) |
CP, chronic phase; CR, complete remission; DRI, Disease Risk Index; IgG, immunoglobulin G; IQR, interquartile range; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm.
One MDS, 1 MDS/MPN, 1 primary myelofibrosis, 1 primary myelofibrosis with transformed lymphoma.
Two peripheral T-cell lymphoma, 1 follicular lymphoma, 1 low-grade lymphoma with multiple myeloma.
One ponatinib, 2 sorafenib.
Refer to supplemental Table 1 for a per-patient list of mismatched HLA alleles.
Three grafts mismatched at 1 class I and 1 class II locus, 1 graft mismatched at 2 class II loci.
Nine grafts mismatched at 1 class I locus, 1 mismatched at DRB1, 1 mismatched at DQB1.
Mismatching in either direction (composite of HLA-A, -B, -Cw, -DRB1, and -DQB1).
Allele-level mismatch without antigen-level mismatch.
Target dose, 4 × 108 nucleated cells/kg ideal body weight.